Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Intensive Pharmacovigilance Program for Elaprase (SHP ELA-701)

NCT03582449 is registered in ClinicalTrials.gov with Shire as lead sponsor.

NCT NCT03582449
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03582449 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Intensive Pharmacovigilance Program for Elaprase (SHP ELA-701)
Lead sponsor
Shire
Phase
Observational
Overall status
Completed
Start date
January 19, 2018
Completion date
May 10, 2020
Enrollment
5 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

hunter syndrome